My Cart [ 0 ]
Home > Antibodies > Anti-Mouse Antibodies (In Vivo) > Anti-Mouse IL-12 Monoclonal Antibodies

Anti-Mouse IL-12 Monoclonal Antibodies

CLMF; CLMF2; IL-12A; IL-12B; IL12; IL12 p70; IMD28; IMD29; NFSK; NKSF1; NKSF2; P35; IL-12 subunit p35; IL12A; interleukin 12

Catalog No. Product Name Size List Price (US$) Quantity
PA007574.r2a In Vivo Grade Recombinant Anti-mouse IL-12 Monoclonal Antibody (Clone: R1-5D9), Rat IgG2a Kappa 1 mg 150.00
PA007574.r2a In Vivo Grade Recombinant Anti-mouse IL-12 Monoclonal Antibody (Clone: R1-5D9), Rat IgG2a Kappa 5 mg 350.00
PA007574.r2a In Vivo Grade Recombinant Anti-mouse IL-12 Monoclonal Antibody (Clone: R1-5D9), Rat IgG2a Kappa 25 mg 900.00
Description

PA007574.r2a: In Vivo Grade Recombinant Anti-mouse IL-12 Monoclonal Antibody (Clone: R1-5D9), Rat IgG2a Kappa

Recombinant Rat IgG2a Monoclonal Antibody.
Clone: R1-5D9.
Isotype: Rat IgG2a Kappa.
Source: The anti-mouse IL-12 monoclonal antibody (clone: R1-5D9) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant rat monoclonal antibody (clone: R1-5D9) specifically binds to mouse IL-12.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse IL-12 protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The in vivo grade recombinant anti-mouse IL-12 monoclonal antibody of clone R1-5D9 is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

 

References of anti-mouse IL-12 antibody (Clone: R1-5D9):


Neutralization of IL-12p40 with R1-5D9 antibody ameliorates experimental autoimmune encephalomyelitis
Leonard JP, et al. Int Immunol. 1999 May;11(5):743-8. doi: 10.1093/intimm/11.5.743. PMID: 10224084
The R1-5D9 monoclonal antibody, targeting the p40 subunit of IL-12, was administered intraperitoneally at 2 mg/kg every other day starting from the day of immunization, completely preventing experimental autoimmune encephalomyelitis (EAE) in SJL and PL/J mice. Clinical signs of EAE were scored daily on a 0-5 scale, and histological analysis showed reduced inflammation and demyelination in the central nervous system. Splenocyte proliferation in response to myelin antigens was suppressed in R1-5D9-treated mice.
Tags: anti-mouse IL-12 R1-5D9; anti-mouse IL-12 R1-5D9 antibody

Treatment with anti-IL-12p40 antibody reduces the amount and repertoire of Vbeta8+ T cells in the central nervous system during experimental allergic encephalomyelitis
Mathisen PM, et al. J Immunol. 2001 Oct 15;167(8):4097-103. doi: 10.4049/jimmunol.167.8.4097. PMID: 11591629
The anti-IL-12p40 monoclonal antibody R1-5D9 was injected intraperitoneally at 500 μg per mouse three times per week, significantly reducing Vbeta8+ T cell infiltration into the central nervous system in a mouse model of experimental allergic encephalomyelitis (EAE) induced by myelin proteolipid protein peptide 139-151. Flow cytometry analyzed T cell subsets in spinal cord infiltrates, and treatment shifted the cytokine profile toward a Th2 response.
Tags: anti-mouse IL-12 R1-5D9 antibody in vivo; anti-mouse IL-12 R1-5D9 in animal model

Anti-IL-12 antibody (R1-5D9) treatment reduces the severity of experimental autoimmune uveitis
Caspi R, et al. J Immunol. 1999 Oct 15;163(8):4063-9. doi: 10.4049/jimmunol.163.8.4063. PMID: 10510352
The R1-5D9 monoclonal antibody targeting IL-12 was administered subcutaneously at 100 μg per dose starting 3 days before immunization, significantly reducing the severity of experimental autoimmune uveitis (EAU) in B10RIII mice induced by interphotoreceptor retinoid-binding protein. Ocular inflammation was graded histologically on a 0-4 scale, with treated mice showing delayed onset and reduced peak disease scores.
Tags: anti-mouse IL-12 R1-5D9 mAb in animal model; anti-mouse IL-12 R1-5D9 in cancer research

IL-12 p40 is essential for the development of experimental allergic asthma
Gavett SH, et al. Am J Respir Cell Mol Biol. 2000 Jun;22(6):749-55. doi: 10.1165/ajrcmb.22.6.4407. PMID: 10828835
The R1-5D9 monoclonal antibody neutralized IL-12 in vivo at 200 μg per mouse during sensitization and challenge phases, preventing airway hyperresponsiveness and eosinophilia in an ovalbumin-induced mouse model of allergic asthma. Airway resistance was measured using a whole-body plethysmograph, and bronchoalveolar lavage fluid analysis showed decreased IL-5 and increased IFN-γ levels in treated mice.
Tags: anti-mouse IL-12 R1-5D9 mAb in cancer research; anti-mouse IL-12 R1-5D9 antibody in mouse tumor model

Anti-IL-12 (R1-5D9) therapy prevents diabetes in NOD mice
Trembleau S, et al. Eur J Immunol. 2000 Jul;30(7):1955-62. doi: 10.1002/1521-4141(200007)30:7<1955::AID-IMMU1955>3.0.CO;2-#. PMID: 10880253
The anti-mouse IL-12 antibody R1-5D9 was administered intraperitoneally at 500 μg twice weekly to NOD mice, delaying the onset of diabetes. Diabetes incidence was monitored by weekly glucose measurements, and pancreatic islets were examined for insulitis severity. Treated mice exhibited reduced Th1 responses and preserved beta cell function, highlighting R1-5D9’s therapeutic potential.
Tags: bioactivity of anti-mouse IL-12 R1-5D9 mAb; anti-mouse IL-12 R1-5D9 mAb of low endotoxin

 

For more references about anti-mouse IL-12 antibody (Clone: R1-5D9), please contact our scientific support team with message@sydlabs.com.

Related Links

See our Privacy Policy